Compare CGEM & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGEM | TALK |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | 521 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.7M | 788.5M |
| IPO Year | 2020 | N/A |
| Metric | CGEM | TALK |
|---|---|---|
| Price | $16.18 | $5.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $30.13 | $6.42 |
| AVG Volume (30 Days) | 778.1K | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.02 |
| Revenue Next Year | $5.20 | $21.24 |
| P/E Ratio | ★ N/A | $155.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $2.22 |
| 52 Week High | $16.74 | $5.20 |
| Indicator | CGEM | TALK |
|---|---|---|
| Relative Strength Index (RSI) | 65.46 | 57.77 |
| Support Level | $11.92 | $4.59 |
| Resistance Level | N/A | $5.19 |
| Average True Range (ATR) | 1.02 | 0.02 |
| MACD | 0.27 | -0.01 |
| Stochastic Oscillator | 92.55 | 50.00 |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.